BridgeBio Pharma Inc vs Fastly Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Fastly Inc trades at $28.5 (market cap $4.58B). The key difference: BridgeBio Pharma Inc is far larger — about 3.6× Fastly Inc's market cap. Which is the better fit depends on your goals.
| BBIO | FSLY | |
|---|---|---|
Market Cap | $16.36B | $4.58B |
Sector | Health | Technology |
52-Week High | $90.17 | $33.50 |
52-Week Low | $47.29 | $6.85 |
Enterprise Value | $18.14B | $4.65B |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →